Clasificación de los linfomas no Hodgkin. Estudio base poblacional del Área Metropolitana de Bucaramanga

García Ramírez, Carlos Alberto; Uribe Pérez, Claudia Janeth

Clasificación de los linfomas no Hodgkin. Estudio base poblacional del Área Metropolitana de Bucaramanga

dc.contributor.apolounab	García Ramírez, Carlos Alberto [carlos-alberto-garcía-ramírez]	spa
dc.contributor.author	García Ramírez, Carlos Alberto
dc.contributor.author	Uribe Pérez, Claudia Janeth
dc.contributor.cvlac	García Ramírez, Carlos Alberto [0000042722]	spa
dc.contributor.orcid	García Ramírez, Carlos Alberto [0000-0002-4727-0708]	spa
dc.coverage.campus	UNAB Campus Bucaramanga	spa
dc.coverage.spatial	Bucaramanga (Santander, Colombia)	spa
dc.date.accessioned	2023-08-02T12:22:01Z
dc.date.available	2023-08-02T12:22:01Z
dc.date.issued	2010-11-18
dc.description.abstract	Los Linfomas no Hodgkin son un grupo de patologías que desde hace muchos años han sido un reto para la medicina, debido a su difícil diagnóstico y manejo, situación que se traduce en un pobre pronóstico para los pacientes. Para hacer un diagnóstico correcto es necesario además de una buena historia clínica, un estudio histopatológico el cual la mayoría de las veces no permite clasificar el linfoma y por lo tanto es necesario recurrir a otras técnicas más especializadas tales como inmunohistoquímica, citometría de flujo o Citogenética. Todo lo anterior trae como consecuencia la demora en un diagnóstico oportuno al paciente y costos para las instituciones de salud. Muchos de estos pacientes fallecen sin un diagnóstico correcto y peor aún sin un tratamiento adecuado. Por otro lado, el tratamiento de los linfomas difiere según el subtipo histológico, situación que hace imprescindible la clasificación de todos los linfomas para el pronóstico y para una terapéutica correcta y adecuada, La incidencia de los LNH varía considerablemente entre los diferentes países, pero se sitúa aproximadamente en 3-6 casos por 100.000 habitantes/ año. Su frecuencia aumenta cada año. Según los datos del Registro de Cáncer del Área Metropolitana de Bucaramanga, el Linfoma no Hodgkin ocupa el noveno lugar de todas las neoplasias malignas. Desde el año 2000 a 2006, se registraron 320 casos de Linfomas no Hodgkin los cuales no están subclasificados. Todo la anterior nos conduce a la necesidad de establecer un mecanismo fácil para lograr la clasificación de los linfomas no Hodakin en los diferentes subtipos histológicos, Lo que fortalece un manejo específico, mejorando la sobrevida. Esta adecuada clasificación, permitirá conocer completamente, el comportamiento epidemiológico de este tipo de lesiones. Es de aclarar que en ningún momento se hará revisión del diagnóstico inicial.	spa
dc.description.abstractenglish	Non-Hodgkin Lymphomas are a group of pathologies that have been a challenge for medicine for many years, due to their difficult diagnosis and management, a situation that translates into a poor prognosis for patients. To make a correct diagnosis, in addition to a good clinical history, a histopathological study is necessary, which most of the time does not allow lymphoma to be classified and therefore it is necessary to resort to other more specialized techniques such as immunohistochemistry, flow cytometry or Cytogenetics. . All of the above results in a delay in a timely diagnosis for the patient and costs for health institutions. Many of these patients die without a correct diagnosis and even worse without adequate treatment. On the other hand, the treatment of lymphomas differs according to the histological subtype, a situation that makes the classification of all lymphomas essential for the prognosis and for correct and adequate therapy. The incidence of NHL varies considerably between different countries, but It is approximately 3-6 cases per 100,000 inhabitants/year. Its frequency increases every year. According to data from the Cancer Registry of the Bucaramanga Metropolitan Area, non-Hodgkin Lymphoma ranks ninth among all malignant neoplasms. From 2000 to 2006, 320 cases of non-Hodgkin lymphomas were registered, which are not subclassified. All of the above leads us to the need to establish an easy mechanism to achieve the classification of non-Hodakin lymphomas into the different histological subtypes, which strengthens specific management, improving survival. This adequate classification will allow us to fully understand the epidemiological behavior of this type of injuries. It should be noted that at no time will the initial diagnosis be reviewed.	eng
dc.description.learningmodality	Modalidad Presencial	spa
dc.format.mimetype	application/pdf	spa
dc.identifier.instname	instname:Universidad Autónoma de Bucaramanga - UNAB	spa
dc.identifier.reponame	reponame:Repositorio Institucional UNAB	spa
dc.identifier.repourl	repourl:https://repository.unab.edu.co	spa
dc.identifier.uri	http://hdl.handle.net/20.500.12749/20968
dc.language.iso	spa	spa
dc.publisher.faculty	Facultad Ciencias de la Salud	spa
dc.publisher.grantor	Universidad Autónoma de Bucaramanga UNAB	spa
dc.relation.references	Ries LAG, Kosary CL, Hankey BF, et al: SEER Cancer Statistics Review, 1973-1996. National Cancer Institite: Bethesda, MD, 1999.
dc.relation.references	James O. Armitage, M.D. and T. Andrew Lister, M.D. American Society of Clinical Oncology; 338-41, 1998.
dc.relation.references	Greiner T., Medeiros J., Jaffe E.S.: Non- Hodgkin's Lymphoma. Cancer; 75: 370-380, 1995.
dc.relation.references	Beahrs OH, Henson DE, Hunter RV, et al: American joint Committee on Cancer: Manual for Stging of Cancer, 4th ed. philadelphia, JB Lippincott, 1992,
dc.relation.references	Gomez Codina J: Pronostic factors on NHL. B and T Lymphomas. Biology,clinical features and treatment.. Ed. IDEPSA; pp 152-186, 1997.
dc.relation.references	Stanfeld A.G., Diebold J., Kapanci Y.: Update Kiel Classification for lymphomas. Lancet; 1: 293-294, 1988.
dc.relation.references	Lukes, R.J., Collins, R.D.: Immunlogical characterization of human malignant lymphomas. Cancer; 34:1488-1503, 1974.
dc.relation.references	Rosenberg, S.A., National Cancer Institute sponsored study of clasifications of non-Hodgkin's lIymphomas, summary and description of a Working Formulation for clinical usage. Cancer; 42: 2112-2135, 1982.
dc.relation.references	Anon: A clinical evaluation of the International Lymphoma Study Group classification of nonHodgkin lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 89: 3909-3918, 1997,
dc.relation.references	Armitage JO, Weisenburger DD: New approach to classifying non- Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin”s Lymphoma Classification Project. J Clin Oncol 16: 2780- 2795, 1998.
dc.relation.references	Harris NL, Jaffe ES, Stein H, et al: A revised European-American Classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood; 84(5): 1361-1392, 1994, 12. Harris
dc.relation.references	Harris NL, Jaffe ES, Diebold J et al: World Health Organization classification of neoplstic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting — Airlie House, Virginia, November 1997. Journal of Clinical Oncology; 17(12):3835- 3849, 1999,
dc.relation.references	Jaffe ES, Harris NL, Stein H, Vardiman JW: World Health Organization classification of tumours of hematopoietic and lymphoid tissues. TARC press, 2001.
dc.relation.references	World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: JARC Press; 2008.
dc.relation.references	Picker L.J., Medeiros L.J., Weiss L.M. and et al: Expression of lymphocyte homing receptor antigen in non-Hodgkin”s lymphoma. Am J Pathol; 130(3): 496-504, 1998.
dc.relation.references	Diaz-Pavon, JR, Cabanillas, F: Treatment of non-Hodgkin's lymphoma. Curr Opin Oncol; 3(5):830-837, 1991.
dc.relation.references	Uribe CJ. Cancer incidence in Bucaramanga Metropolitan Area, 2000-2004. Medunab. Vol. 10 Número 3, Noviembre de 2007
dc.relation.references	Fritz A, Percy C, Jack A, Sobin L, Parkin M, Whelan S (ed). ICD-0-3. Geneva (Switzerland), WHO, 2000.
dc.relation.references	Shipp MA. A predictive model for aggressive non- Hodgkin's lymphoma. The International Non- Hodgkin”s Lymphoma Prognostic Factors Project. N Engl J Med; 329: 987-994, 1993.
dc.relation.references	Ffrech M; Magaud JP; Ffrench P and el al: Heterogeneity of neoplastic and reactive cell proliferation in non-Hodgkin”s iymphomas linked to patient survival. Am J Clin Pathol; 101: 413- 420, 1994.
dc.relation.references	Vose JM. Current approaches to the management of non-Hodgkin”s Iymphoma.; Semin Oncol. 25:483-491.1998
dc.relation.references	Nadler LM, Anderson KC, Marti LG, et al: B4, a human B lymphociteassociated antigen expressed on normal mitogen activated, and malignant B lymphocytes. J Immunol; 131: 244, 1983.
dc.relation.references	Campana D, Janossy G, Bofill M, et al: Human B cell development: Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissues. J Immunol; 134: 1524, 1985.
dc.relation.references	Armitage JO: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin lymphoma. Blood; 89: 3909-3918, 1997.
dc.relation.references	Pasqualucci 1 and Dalla-Favera R: Molecular patogénesis of non- Hodgkin”s lymphomas. ASH: 200-205, 2001.
dc.relation.references	Ries LAG, Miller BA, Hankey BF, et al (eds): SEER Cancer Statistics Review, 1973-1991: Tables and graphs, National Cancer Institute. NIH publication No. 94-2789. Bethesda, MD, US Departament of Health and Human Services, 1994.
dc.relation.references	Sutcliffe SB, Gospodarowiez MK,: Localized extranodal lymphomas. In Keating A, Armitage J, Bumett A, et al (eds): Hematological Oncology. Cambridge, Cambridge University Press, pp 189- 222, 1992,
dc.relation.references	Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal Iymphomas. Cancer; 29:252-260, 1972.
dc.relation.references	Aisenberg AC. Extranodal lymphoma: presentation, natural history,and special treatment considerations in Malignant lymphoma.Biology, natural history and treatment, Lea dz Febiger edits; 235-310. 1991.
dc.relation.references	Vindelow LL, Christensen 1J, Nissen NI: Limits of detection of nuclear DNA abnormalities by flow cytometric DNA analysis. Results obtained by a set of methods for sample storage, staining and internal standardization. Cytometry; 3:332-339, 1983.
dc.relation.references	Carter NP, Meyer EW: Introduction to the principles of flow cytometry. En: Flow Cytometry, a practical approach. Editor: Ormerod, M.G.: IRL Press, Oxford University Press, Oxford, 1990.
dc.rights.accessrights	info:eu-repo/semantics/openAccess	spa
dc.rights.creativecommons	Atribución-NoComercial-SinDerivadas 2.5 Colombia	*
dc.rights.local	Abierto (Texto Completo)	spa
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/2.5/co/	*
dc.subject.keywords	Complex diseases	spa
dc.subject.keywords	Genetic study	spa
dc.subject.keywords	Lymphatic system	spa
dc.subject.keywords	Immune system	spa
dc.subject.keywords	Baseline study	spa
dc.subject.keywords	Population dynamics	spa
dc.subject.lemb	Cáncer	spa
dc.subject.lemb	Sistema linfático	spa
dc.subject.lemb	Sistema inmune	spa
dc.subject.lemb	Dinámica de la población	spa
dc.subject.proposal	Enfermedades complejas	spa
dc.subject.proposal	Estudio genético	spa
dc.subject.proposal	Estudio base	spa
dc.title	Clasificación de los linfomas no Hodgkin. Estudio base poblacional del Área Metropolitana de Bucaramanga	spa
dc.title.translated	Classification of non-Hodgkin lymphomas. Population-based study of the Metropolitan Area of Bucaramanga	spa
dc.type	Research report	eng
dc.type.coar	http://purl.org/coar/resource_type/c_18ws
dc.type.coarversion	http://purl.org/coar/version/c_ab4af688f83e57aa	spa
dc.type.driver	info:eu-repo/semantics/workingPaper	spa
dc.type.hasversion	info:eu-repo/semantics/acceptedVersion	spa
dc.type.local	Informe de investigación	spa
dc.type.redcol	http://purl.org/redcol/resource_type/IFI	spa